The Centers for Medicare & Medicaid Services released preliminary information for the 2027 Medicare Clinical Laboratory Fee Schedule on September 21, setting up a payment update that laboratory leaders should examine before completing next year’s budgets. CMS expects to finalize the rates in November, with payments taking effect January 1, 2027.
For laboratories, the immediate task is to identify which tests drive their exposure and how the eventual rates could affect revenue.
Medicare generally bases these laboratory payments on the weighted median of private-payer rates reported by applicable laboratories. The latest reporting cycle used information collected from January through June 2025 and submitted between May and July 2026.
CMS’s fact sheet describes an average potential change approximately 16% below 2026 rates. Among codes with reported private-payer medians, 1,171 had a median below the comparable 2026 Medicare rate, while others were unchanged or higher. The impact therefore varies by test.
That variation matters more to an individual laboratory than the headline average. A laboratory’s exposure depends on its mix of tests, Medicare volume, and the eventual payment assigned to each code.
How the reduction cap affects planning
CMS explains that payment reductions for an individual test are limited to 15% per year during 2027–2029, compared with the preceding year’s payment. That limit governs the annual adjustment; it does not mean every test receives a 15% reduction.
Consider a simplified planning example. If a test’s 2026 payment were $10 and its new benchmark were $8, applying a 15% annual reduction cap would produce an $8.50 payment for the first year.
At 10,000 paid tests, that would represent $15,000 less annual revenue, assuming volume remained constant. This is an illustration, not a forecast for a particular code or laboratory.
A useful budget model should separate the payment change from assumptions about test volume, collection costs, staffing, and other operating expenses.
What laboratory teams can review now
Finance and revenue-cycle teams can start by matching their highest-volume Medicare test codes against the preliminary information. For each code, record the current payment, potential new payment, annual volume, and estimated revenue difference.
Next, rank the results by total dollars at risk. A modest change in a frequently performed test may deserve more attention than a larger percentage change in a rarely billed service.
Keep unresolved rates and missing information visible in the model. Treating an unknown payment as unchanged can make a budget appear more certain than the evidence supports.
Laboratories reviewing the methodology also have a specific issue to examine: CMS removed duplicate records and certain extreme payment outliers, and published comparisons with and without those exclusions. The agency is seeking feedback on that approach.
The next decision points
CMS announced a 30-day comment period beginning September 21 for the preliminary rates and supporting data. Its projected $1 billion in annual savings is an agency estimate, rather than an observed result.
The November release will provide the next basis for updating budgets. Until then, laboratories can use scenario planning to identify their exposure, document uncertainties, and prepare focused questions about the tests that matter most to their operations.